Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corp (NASDAQ: ABUS) generates news primarily through clinical trial updates, scientific conference presentations, and corporate milestones in its pursuit of hepatitis B virus (HBV) cure therapies. As a clinical-stage biopharmaceutical company, Arbutus regularly reports on the progress of its drug candidates through the development pipeline.
News coverage for Arbutus typically includes clinical trial data readouts for imdusiran and AB-101, the company's lead HBV drug candidates. Investors and researchers monitoring HBV therapeutic development follow these updates closely, as trial results shape understanding of whether combination approaches can achieve functional cure. Conference presentations at major hepatology meetings provide additional scientific detail beyond press releases.
Quarterly financial reports reveal the company's cash position and operating expenses, critical metrics for clinical-stage biotechs that rely on financing rather than product revenue. These reports often coincide with pipeline updates and forward-looking guidance on clinical timelines. Partnership announcements and licensing deals related to Arbutus's lipid nanoparticle (LNP) technology platform also generate coverage.
Regulatory interactions, including FDA communications and clinical trial design decisions, inform expectations about development pathways. Board and leadership changes affect corporate strategy and investor sentiment. For those tracking the competitive HBV cure landscape, Arbutus news provides insight into one focused player's progress toward transforming chronic infection treatment.
Bookmark this page to follow Arbutus Biopharma's clinical development progress and corporate updates as the company advances its hepatitis B cure programs.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that CEO William Collier will present at the Jefferies London Healthcare Conference on November 16, 2022, at 11:30 am GMT / 6:30 am EDT. The presentation will be accessible via a live webcast on Arbutus' website, with an archived replay available afterward. Arbutus is focused on developing therapeutics for viral diseases, particularly Hepatitis B and coronaviruses, with key compounds like AB-729 currently in phase 2 clinical trials.
Arbutus Biopharma (ABUS) announced promising findings from clinical trials of its RNAi therapeutic, AB-729, showing sustained HBV suppression in patients up to 44 weeks after treatment cessation. Additionally, preclinical data for AB-101, an oral PD-L1 inhibitor, indicate improved HBV immune response when combined with RNAi therapy. However, the company has halted AB-836 development due to safety concerns. Upcoming poster presentations at the AASLD – The Liver Meeting will detail these findings. A conference call is scheduled for November 4, 2022, to discuss these results.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that it will present three posters with clinical data at the AASLD Liver Meeting 2022 from November 4-8 in Washington, DC. The presentations will cover findings from its lead compound AB-729 and the preclinical PD-L1 inhibitor AB-101. Key data highlights include:
- Long-term HBV control in patients after stopping nucleos(t)ide analogue therapy.
- Increased immune responses in HBV-infected mice with combined treatment.
- Interim analysis of a Phase 2 study showing safety in various treatment combinations.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its schedule for the third quarter 2022 financial results and corporate update, set for November 9, 2022. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET.
The company focuses on developing therapeutics for viral diseases, including HBV and SARS-CoV-2. Notably, its lead compound AB-729 is undergoing evaluation in multiple phase 2 clinical trials.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that Chief Development Officer Gaston Picchio will depart for personal reasons effective December 31, 2022. The company has begun the search for his successor. CEO William Collier expressed gratitude for Dr. Picchio's contributions, particularly in advancing the clinical pipeline targeting chronic hepatitis B virus (HBV). Arbutus focuses on developing therapeutics aimed at HBV and other viral diseases, including its lead RNAi therapeutic, AB-729, currently in multiple Phase 2 clinical trials.
Arbutus Biopharma Corporation (Nasdaq: ABUS) will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, at 2:30 pm ET. Key executives, including President & CEO William Collier and Chief Scientific Officer Dr. Michael Sofia, will present. A live webcast is available on the company’s website, and an archived replay will follow. Arbutus focuses on discovering therapeutics for viral diseases, particularly Hepatitis B and SARS-CoV-2, with ongoing phase 2 trials for its lead compound AB-729.
WARMINSTER, Pa., Sept. 06, 2022 – Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in two upcoming investor conferences in New York. They will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13 at 12:30 PM ET, with CEO William Collier as the presenter. Additionally, they will hold a fireside chat at Baird's 2022 Global Healthcare Conference on September 14 at 10:15 AM ET. Live webcasts will be available on their website, with replays accessible post-event.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the issuance of U.S. Patent No. 11,427,823 by the USPTO, granting composition of matter protection for its AB-729 RNAi therapeutic. This patent extends exclusivity for AB-729 until at least April 2038. The company is advancing AB-729 through multiple Phase 2a clinical trials, showing promising safety and efficacy, with significant reductions in hepatitis B surface antigen and DNA levels. Arbutus aims to address the unmet medical needs of over 290 million chronic hepatitis B virus patients globally.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported their second quarter 2022 financial results, showing a strong financial position with cash and equivalents of $200.6 million, ensuring a runway into Q2 2024. Revenue surged to $14.2 million, up from $2.3 million a year earlier, primarily due to a license agreement with Qilu Pharmaceutical. Clinical advancements were made in their hepatitis B and pan-coronavirus programs, including promising data from their lead therapies AB-729 and AB-836. The company remains focused on its pipeline and upcoming trials.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its second quarter 2022 financial results and corporate update on August 4, 2022. The company will release its Q2/2022 press release at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. Investors can access the live webcast through the Investors section of Arbutus' website. The company focuses on innovative therapeutics for viral diseases, including Hepatitis B and coronaviruses, and is advancing its lead compound, AB-729, in multiple phase 2 clinical trials.
FAQ
What is the current stock price of Arbutus Biopharm (ABUS)?
What is the market cap of Arbutus Biopharm (ABUS)?
